Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted in part — page 3

Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.

Submissions

377 documents · page 3 of 13

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-GASTROPARESI/002Draft safety review: delayed gastric emptying and procedural sedationDr Frideswide HazelriggStatistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-THYROID-C-CE/005Draft safety review: the rodent thyroid C-cell signal and its human…Dr Delphine RavensworthReferences should carry a persistent identifier for every cited source
DRAFT-THYROID-C-CE/010Draft safety review: the rodent thyroid C-cell signal and its human…Dr Quentin ZimmerthalA surrogate outcome is used as the anchor without validation evidence
DRAFT-THYROID-C-CE/011Draft safety review: the rodent thyroid C-cell signal and its human…Dr Emiliana OllerenshawPoint estimates are given without an interval
DRAFT-THYROID-C-CE/004Draft safety review: the rodent thyroid C-cell signal and its human…Dr Ulysses Bellingham-Ojo industryA sponsor trial meeting the eligibility criteria was excluded
DRAFT-THYROID-C-CE/002Draft safety review: the rodent thyroid C-cell signal and its human…Dr Wolfram TollemacheTwo included studies do not meet the registered eligibility criteria
DRAFT-THYROID-C-CE/012Draft safety review: the rodent thyroid C-cell signal and its human…Dr Quentin EnthovenThe document is unreadable without specialist training
DRAFT-THYROID-C-CE/008Draft safety review: the rodent thyroid C-cell signal and its human…Dr Jerome LavrentievStatistical heterogeneity is treated as though it measured clinical heterogeneity
DRAFT-SUPPLIER-DOS/010Draft format of the supplier dossier seriesDr Fenella LavrentievThe front matter delays the reader from reaching the assessment
DRAFT-SUPPLIER-DOS/004Draft format of the supplier dossier seriesDr Eamon ImmelmannReferences should carry a persistent identifier for every cited source
DRAFT-PEOPLE-REGIS/010Draft policy on the register of members and reviewersDr Gervase AbergavennyThe document is unreadable without specialist training
DRAFT-CORRECTIONS-/003Draft corrections and versioning policyDr Ulysses Bellingham-OjoPoint estimates are given without an interval
DRAFT-CORRECTIONS-/019Draft corrections and versioning policyDr Hyacinth Oyelaran-SteenReferences should carry a persistent identifier for every cited source
DRAFT-CORRECTIONS-/013Draft corrections and versioning policyDr Georgiana MountstephenThe threshold between a correction and a new version is drawn too high
DRAFT-CORRECTIONS-/001Draft corrections and versioning policyDr Wilhelmina QuaresmaFunding should not be accepted from any party the Institute assesses
DRAFT-CORRECTIONS-/002Draft corrections and versioning policyIvo MountstephenThe materiality threshold for a declarable holding is set too high
DRAFT-CORRECTIONS-/014Draft corrections and versioning policyDr Jolanta UttridgeThe document is unreadable without specialist training
DRAFT-STABILITY-ST/007Draft standard: freeze–thaw and in-use stability assessment of…Dr Xenia UttridgeReferences should carry a persistent identifier for every cited source
DRAFT-STABILITY-ST/010Draft standard: freeze–thaw and in-use stability assessment of…Professor Ekaterina Voskresenskaya-HillPoint estimates are given without an interval
DRAFT-STABILITY-ST/005Draft standard: freeze–thaw and in-use stability assessment of…Kolawole Jankowiak-OseiThe document is unreadable without specialist training
DRAFT-STABILITY-ST/002Draft standard: freeze–thaw and in-use stability assessment of…Dr Jolanta UttridgeAcceptance criteria are expressed in terms specific to one instrument family
DRAFT-INDICATION-S/010Draft indication set and anchor outcomesDr Mordecai Glendinning-UcheA fixed section structure will force empty sections
DRAFT-INDICATION-S/015Draft indication set and anchor outcomesDr Anselm Thorsby-NakamuraThe series scope is drawn widely enough to absorb documents that belong elsewhere
DRAFT-INDICATION-S/004Draft indication set and anchor outcomesDr Vasilisa ImmelmannPoint estimates are given without an interval
DRAFT-INDICATION-S/007Draft indication set and anchor outcomesDr Eamon ImmelmannThe document is unreadable without specialist training
DRAFT-MASH-SYNTHES/005Draft synthesis: incretin receptor agonists for metabolic…Dr Katarzyna YorkstonePoint estimates are given without an interval
DRAFT-MASH-SYNTHES/007Draft synthesis: incretin receptor agonists for metabolic…Yusuf Whitmarsh-ObiThe choice of effect measure is not justified and changes the appearance of the result
DRAFT-MASH-SYNTHES/001Draft synthesis: incretin receptor agonists for metabolic…Radoslava Palmgren-KofiSubgroup findings are reported that were not registered in the protocol
DRAFT-MASH-SYNTHES/006Draft synthesis: incretin receptor agonists for metabolic…Dr Lorcan Zaleski-MbekiRegulatory assessment documents were not searched
DRAFT-ADOLESCENT-S/004Draft synthesis: incretin receptor agonists in adolescentsDr Frideswide HazelriggPoint estimates are given without an interval

page 3 of 13

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.